NBPF5P Antibody

What is NBPF5P and why is it significant for neuroblastoma research?

NBPF5P (also known as neuroblastoma breakpoint family member 5 pseudogene) is a member of the neuroblastoma breakpoint family that has been linked to neuroblastoma development. This protein is significant because it may play a role in the molecular pathways involved in neuroblastoma, a type of cancer that originates in nerve tissue. Research into the function and expression of NBPF5P can provide valuable insights into the mechanisms underlying neuroblastoma and potentially lead to new diagnostic and therapeutic strategies for this aggressive cancer .

The NBPF gene family is characterized by multiple copies clustered in the p36, p12, and q21 regions of chromosome 1 . Understanding the role of NBPF5P in normal cellular processes and in disease states can contribute to a deeper understanding of neuroblastoma pathogenesis.

What are the key specifications of commercially available NBPF5P antibodies?

Most commercial NBPF5P antibodies share the following specifications:

The antibodies are typically generated using synthetic peptides derived from the C-terminal region of human NBPF5 as immunogens .

What are the recommended applications for NBPF5P antibody?

NBPF5P antibodies are validated for multiple experimental applications:

• Western Blot (WB): For detecting NBPF5P protein in cell or tissue lysates. Typically used at dilutions of 1:500-1:3000 .

• Immunohistochemistry (IHC): For visualizing the distribution and localization of NBPF5P in tissue sections. Recommended dilutions range from 1:100-1:300 .

• Immunocytochemistry (ICC)/Immunofluorescence (IF): For detecting NBPF5P in cultured cells. Typically used at dilutions of 1:50-1:200 .

• ELISA: For quantitative measurement of NBPF5P in solution. Usually used at higher dilutions (1:10000) .

• Flow Cytometry (FC/FACS): Some antibodies are validated for detection of NBPF5P in flow cytometry applications .

Each application requires specific optimization of antibody concentration, incubation conditions, and detection methods for optimal results.

How should I optimize Western blot conditions for NBPF5P detection?

When optimizing Western blot conditions for NBPF5P detection, consider the following methodological approach:

• Sample Preparation:

  • Extract proteins from cell lines with known NBPF5P expression (e.g., Jurkat, K562 cells have been validated)

  • Use a lysis buffer containing protease inhibitors to prevent protein degradation

• Protein Loading and Separation:

  • Load 20-40 μg of total protein per lane

  • Use 10-12% SDS-PAGE gels for optimal separation of the ~41 kDa NBPF5P protein

• Transfer and Blocking:

  • Transfer proteins to PVDF or nitrocellulose membranes

  • Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Antibody Incubation:

  • Start with a 1:1000 dilution of primary antibody in blocking buffer

  • Incubate overnight at 4°C for optimal binding

  • Use appropriate HRP-conjugated secondary antibody (typically anti-rabbit IgG) at 1:5000-1:10000 dilution

• Detection:

  • Develop using ECL substrate and adjust exposure time based on signal intensity

  • The expected molecular weight for NBPF5P is approximately 41 kDa, though observed weights around 72 kDa have been reported

• Controls:

  • Include positive control (e.g., Jurkat cell lysate)

  • Consider using a blocking peptide control to confirm specificity

Optimization may require adjusting antibody concentrations, incubation times, or detection methods based on your specific experimental conditions.

What are the key considerations for immunohistochemical detection of NBPF5P in tissue samples?

For successful immunohistochemical detection of NBPF5P in tissue samples:

• Tissue Processing and Antigen Retrieval:

  • Use formalin-fixed, paraffin-embedded (FFPE) or frozen tissue sections

  • For FFPE sections, perform antigen retrieval using Tris-EDTA buffer (pH 9.0) for optimal results

  • Heat-induced epitope retrieval (HIER) is typically more effective than enzymatic methods

• Blocking and Antibody Incubation:

  • Block endogenous peroxidase activity with 3% H₂O₂

  • Block non-specific binding with 5-10% normal serum

  • Use NBPF5P antibody at 1:100-1:300 dilution

  • Incubate overnight at 4°C for optimal sensitivity and specificity

• Detection System:

  • Use appropriate secondary antibody (anti-rabbit) at 1:200 dilution

  • Incubate for 45 minutes at room temperature

  • Develop with DAB and counterstain with hematoxylin

• Controls and Validation:

  • Include positive control tissues (human tonsil has been validated)

  • Include negative controls (omitting primary antibody)

  • Consider dual staining with cell-type specific markers for co-localization studies

• Signal Interpretation:

  • Look for cytoplasmic staining patterns based on predicted subcellular localization

  • Assess both staining intensity and distribution pattern

  • Compare with normal adjacent tissue when analyzing diseased samples

These protocols should be optimized for each specific tissue type and experimental condition.

How can I use NBPF5P antibody for studying neuroblastoma development and progression?

NBPF5P antibody can be employed in several advanced approaches to study neuroblastoma:

• Expression Profiling in Clinical Samples:

  • Compare NBPF5P expression in neuroblastoma samples versus normal neural tissues

  • Correlate expression levels with clinical parameters (stage, prognosis, treatment response)

  • Use IHC on tissue microarrays for high-throughput analysis

• Functional Studies:

  • Combine with siRNA/shRNA knockdown experiments to assess functional consequences of NBPF5P depletion

  • Use the antibody to validate knockdown efficiency in Western blot

  • Analyze phenotypic changes (proliferation, migration, invasion) after manipulation of NBPF5P expression

• Signaling Pathway Analysis:

  • Use co-immunoprecipitation with NBPF5P antibody to identify interaction partners

  • Perform immunofluorescence co-localization studies with other neuroblastoma-related proteins

  • Investigate NBPF5P expression after treatment with pathway inhibitors to position it within signaling networks

• Biomarker Development:

  • Evaluate NBPF5P as a potential diagnostic or prognostic biomarker

  • Develop quantitative assays (ELISA) for NBPF5P detection in patient samples

  • Correlate with existing neuroblastoma biomarkers to establish complementary value

• Therapeutic Target Validation:

  • Monitor changes in NBPF5P expression after treatment with potential therapeutic agents

  • Use the antibody to confirm target engagement in drug development studies

This multi-faceted approach can provide comprehensive insights into the role of NBPF5P in neuroblastoma pathogenesis and its potential as a therapeutic target.

What approaches can I use to validate NBPF5P antibody specificity for my research?

Thorough validation of NBPF5P antibody specificity is crucial for reliable research outcomes. Consider implementing these approaches:

• Genetic Validation:

  • Test the antibody in NBPF5P-knockout or knockdown models

  • The signal should be significantly reduced or absent in these models

  • Complementary overexpression studies should show increased signal intensity

• Peptide Competition Assays:

  • Pre-incubate the antibody with excess immunizing peptide

  • This should block specific binding and eliminate or significantly reduce the signal

  • Some suppliers offer blocking peptides specifically designed for their antibodies

• Multi-Antibody Validation:

  • Compare results using antibodies from different suppliers or those targeting different epitopes

  • Consistent results across multiple antibodies increase confidence in specificity

• Cross-Reactivity Assessment:

  • Test the antibody on samples from species not listed in the reactivity profile

  • Absence of signal in non-reactive species confirms specificity

  • Consider testing in monkey tissues if working with primate models

• Mass Spectrometry Validation:

  • Perform immunoprecipitation using the NBPF5P antibody

  • Analyze the precipitated proteins by mass spectrometry

  • Confirm the presence of NBPF5P peptides in the immunoprecipitated material

• Western Blot Analysis:

  • Verify a single band at the expected molecular weight (~41 kDa)

  • Multiple bands may indicate non-specific binding or detection of related proteins

  • Some variation in observed molecular weight (e.g., 72 kDa) may occur due to post-translational modifications

These validation approaches should be documented thoroughly to support the reliability of your research findings.

How do I troubleshoot inconsistent NBPF5P antibody performance across different experimental setups?

When encountering inconsistent NBPF5P antibody performance, systematically address these common issues:

• Sample Preparation Variations:

  • Ensure consistent protein extraction methods across experiments

  • Verify protein integrity and concentration before each experiment

  • Use freshly prepared samples when possible to avoid degradation

• Antibody Storage and Handling:

  • Avoid repeated freeze-thaw cycles of antibody aliquots

  • Store according to manufacturer recommendations (typically -20°C)

  • For frequent use, consider storing working aliquots at 4°C for up to one month

• Protocol Optimization:

  • Titrate antibody concentration for each specific application

  • Optimize incubation conditions (time, temperature)

  • Adjust blocking reagents to reduce background (try both milk and BSA)

• Buffer Composition Effects:

  • Ensure consistent buffer composition across experiments

  • Monitor pH stability of buffers

  • Consider testing different detergent concentrations in wash buffers

• Detection System Variables:

  • Compare different detection methods (chemiluminescence vs. fluorescence)

  • Evaluate secondary antibody performance and specificity

  • Check equipment settings and calibration if using imaging systems

• Cell/Tissue-Specific Factors:

  • Different cell types may require protocol adjustments

  • Consider cell-specific expression levels and localization patterns

  • Tissue fixation methods may affect epitope accessibility

• Antibody Lot Variations:

  • Document lot numbers and compare performance between lots

  • Request technical support from manufacturers if lot-to-lot variation is observed

Systematic documentation of these variables will help identify the source of inconsistency and establish reproducible experimental conditions.

How does NBPF5P antibody performance compare across different neuroblastoma cell lines and tissue types?

Based on published research, NBPF5P antibody performance varies across different cell lines and tissues:

For optimal results:

• Cell Line Selection:

  • Jurkat cells consistently show strong NBPF5P expression and serve as excellent positive controls

  • Consider using neuroblastoma-specific cell lines (e.g., SH-SY5Y, SK-N-SH, IMR-32) for disease-relevant models

  • Match cell lines to your research question (differentiation state, genetic background)

• Tissue Analysis Considerations:

  • Human tonsil tissue has been validated for IHC applications

  • Neural tissues and neuroblastoma samples likely show variable expression

  • Consider using tissue microarrays for high-throughput screening across multiple samples

• Protocol Adjustments:

  • Different tissue types may require specific antigen retrieval methods

  • Adjust antibody concentration based on expression levels in specific samples

  • Optimize incubation times for each sample type

This comparative approach helps establish reliable detection protocols across diverse experimental materials.

What are the best practices for using NBPF5P antibody in multiplexed immunofluorescence studies?

For successful multiplexed immunofluorescence incorporating NBPF5P antibody:

• Antibody Panel Design:

  • Select antibodies raised in different host species to avoid cross-reactivity

  • If using multiple rabbit antibodies, consider sequential staining with thorough washing

  • Plan fluorophore selection to minimize spectral overlap

• Staining Protocol Optimization:

  • Start with a 1:50-1:200 dilution of NBPF5P antibody for immunofluorescence

  • Determine optimal fixation methods (4% paraformaldehyde typically works well)

  • Test different permeabilization conditions to ensure antibody access

• Controls and Validation:

  • Include single-color controls to assess bleed-through

  • Use appropriate blocking to minimize non-specific binding

  • Validate each antibody individually before combining them

• Image Acquisition Settings:

  • Optimize exposure settings for each channel separately

  • Use sequential scanning rather than simultaneous acquisition

  • Apply consistent settings across all samples for comparative analysis

• Advanced Multiplexing Approaches:

  • Consider tyramide signal amplification for weakly expressed targets

  • Evaluate spectral unmixing for closely overlapping fluorophores

  • For highly complex panels, investigate cyclic immunofluorescence methods

These practices ensure reliable detection of NBPF5P alongside other targets of interest in complex tissue architectures.

Can NBPF5P antibody be used effectively in non-human experimental models?

The use of NBPF5P antibody in non-human models requires careful consideration:

• Species Cross-Reactivity Profile:

  • Most commercial NBPF5P antibodies are generated against human sequences

  • Some antibodies show cross-reactivity with mouse and rat samples

  • Cross-reactivity with monkey tissues has been queried but requires validation

• Sequence Homology Considerations:

  • Check sequence homology between human NBPF5P and the target species

  • Higher homology in the immunogen region (typically C-terminal) suggests better cross-reactivity

  • Consider custom antibody development for poorly conserved regions

• Validation in Non-Human Systems:

  • Always perform thorough validation in your specific model organism

  • Include appropriate positive and negative controls

  • Consider western blot validation before attempting more complex applications

• Alternative Approaches:

  • For species where cross-reactivity is poor, consider targeting orthologs with species-specific antibodies

  • RNA-level detection methods may complement protein studies

  • Consider generating species-specific antibodies for critical experiments

• Documented Cross-Species Applications:

  • Some NBPF5P antibodies have been validated for human, mouse, and rat samples

  • Validation in monkey tissues has been specifically requested by researchers but results are not documented

This careful approach to cross-species applications ensures reliable interpretation of results in non-human models.

How might single-domain antibodies (nanobodies) advance NBPF5P research compared to conventional antibodies?

Single-domain antibodies (nanobodies) represent an emerging technology with potential advantages for NBPF5P research:

• Structural and Binding Advantages:

  • Nanobodies' smaller size (~15 kDa vs. ~150 kDa for conventional antibodies) may provide better tissue penetration

  • Their single-domain structure could access epitopes that are inaccessible to conventional antibodies

  • Higher stability under varying conditions may improve consistency in challenging applications

• Application-Specific Benefits:

  • Super-resolution microscopy: Nanobodies' smaller size reduces the distance between fluorophore and target

  • Intracellular applications: Some nanobodies can function in the reducing intracellular environment

  • Live-cell imaging: Non-disruptive binding may allow dynamic studies of NBPF5P

• Development Considerations:

  • Nanobodies are typically derived from camelid heavy-chain antibodies through an evolutionary adaptation process

  • Their generation involves immunization, library construction, and selection processes

  • Commercial availability for NBPF5P-specific nanobodies would need to be established

• Potential Research Applications:

  • Tracking NBPF5P dynamics in live neuroblastoma cells

  • Probing protein-protein interactions with minimal steric hindrance

  • Developing targeted therapeutic approaches with improved tissue penetration

• Comparative Analysis:

  Feature	Conventional NBPF5P Antibodies	Potential NBPF5P Nanobodies
  Size	~150 kDa	~15 kDa
  Epitope Access	May be limited for some conformations	Potentially improved for cryptic epitopes
  Applications	WB, IHC, ICC, IF, ELISA	Same, plus potential for intracellular targeting
  Production	Well-established	Requires specialized techniques
  Commercial Availability	Multiple options	Currently lacking

The evolution of nanobody technology represents a promising direction for advancing NBPF5P research, particularly for dynamic cellular studies and therapeutic applications .

What are the emerging applications of NBPF5P antibody in cancer biomarker research?

NBPF5P antibody has several emerging applications in cancer biomarker research:

• Diagnostic Biomarker Development:

  • Developing immunoassays for NBPF5P detection in patient samples (blood, cerebrospinal fluid)

  • Evaluating NBPF5P expression in circulating tumor cells

  • Creating multiplex panels combining NBPF5P with established neuroblastoma markers

• Prognostic and Predictive Applications:

  • Correlating NBPF5P expression levels with patient outcomes

  • Investigating whether NBPF5P expression predicts response to specific therapies

  • Developing scoring systems incorporating NBPF5P status for risk stratification

• Liquid Biopsy Approaches:

  • Detecting NBPF5P in extracellular vesicles (exosomes) from patient plasma

  • Monitoring treatment response through sequential NBPF5P measurements

  • Combining with circulating tumor DNA analysis for comprehensive tumor profiling

• Technological Innovations:

  • Adapting NBPF5P antibodies for point-of-care diagnostic platforms

  • Developing antibody-based capture systems for isolation of NBPF5P-expressing cells

  • Creating antibody-drug conjugates targeting NBPF5P-expressing cancer cells

• Multidisciplinary Integration:

  • Correlating NBPF5P protein expression with genomic and transcriptomic signatures

  • Incorporating NBPF5P status into artificial intelligence algorithms for cancer classification

  • Establishing NBPF5P as part of comprehensive molecular tumor profiling

These emerging applications highlight the potential of NBPF5P antibody to contribute significantly to cancer biomarker research beyond its current experimental applications.

How do I resolve specificity concerns when working with NBPF5P antibody in research applications?

Resolving specificity concerns with NBPF5P antibody requires a systematic approach:

• Understanding Potential Cross-Reactivity:

  • NBPF family has multiple members with sequence similarity

  • NBPF5P is a pseudogene, which may complicate interpretation of results

  • The immunogen used for antibody production is critical for specificity

• Comprehensive Validation Strategy:

  • Genetic Controls: Use CRISPR/Cas9 knockout or siRNA knockdown of NBPF5P

  • Peptide Competition: Pre-incubate antibody with the immunizing peptide

  • Orthogonal Methods: Confirm findings with RNA-level detection methods (qPCR, RNA-seq)

  • Multiple Antibodies: Compare results from antibodies targeting different epitopes

• Application-Specific Considerations:

  Application	Specificity Challenge	Solution
  Western Blot	Multiple bands	Verify expected molecular weight (41 kDa), use positive control cells
  IHC/ICC	Background staining	Optimize blocking, include isotype controls, use antigen competition
  IP	Co-precipitation of related proteins	Validate by mass spectrometry, use stringent wash conditions

• Protocol Optimization:

  • Increase antibody dilution to reduce non-specific binding

  • Optimize blocking conditions (test different blockers like BSA, milk, normal serum)

  • Increase wash duration and stringency to remove weakly bound antibody

• Data Interpretation Guidelines:

  • Always include appropriate positive and negative controls

  • Be cautious about interpreting results solely based on antibody detection

  • Combine multiple detection methods for conclusive results

Addressing specificity concerns through these systematic approaches ensures reliable and reproducible research outcomes when working with NBPF5P antibody.

How can NBPF5P antibody facilitate interdisciplinary research between cancer biology and neuroscience?

NBPF5P antibody can serve as a valuable tool bridging cancer biology and neuroscience research:

• Neuroblastoma as an Intersection Point:

  • Neuroblastoma originates from neural crest cells, making it relevant to both fields

  • NBPF5P expression in neural development and neuroblastoma provides a common focus

  • The antibody enables parallel studies in normal neural development and pathological states

• Collaborative Research Frameworks:

  • Developmental Biology: Tracing NBPF5P expression during neural crest development

  • Cancer Biology: Mapping NBPF5P alterations in neuroblastoma progression

  • Neuroscience: Investigating potential functions in neural circuit formation

• Technical Integration Opportunities:

  • Combining NBPF5P antibody staining with neuron-specific markers

  • Correlating NBPF5P expression with electrophysiological properties

  • Integrating NBPF5P detection in 3D neural organoid models

• Translational Research Avenues:

  • Developing neural differentiation protocols guided by NBPF5P expression patterns

  • Identifying neural subpopulations vulnerable to neuroblastoma transformation

  • Investigating NBPF5P in neurodevelopmental disorders and neural cancers

• Methodological Synergies:

  • Applying neuroscience imaging techniques to cancer biology questions

  • Adapting cancer drug screening platforms for neurodevelopmental research

  • Utilizing neural tracing methods to understand tumor invasion patterns

This interdisciplinary approach could yield novel insights into both neurological development and cancer biology, potentially revealing new therapeutic targets at their intersection.